Prior Frequent Emergency Department Use as a Predictor of Emergency Department Visits After a New Cancer Diagnosis.

Autor:	Hong AS; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX., Nguyen DQ; University of Texas Southwestern Medical School, Dallas, TX., Lee SC; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX., Courtney DM; Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Sweetenham JW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX., Sadeghi N; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX.; Parkland Health & Hospital System, Dallas, TX., Cox JV; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX.; Parkland Health & Hospital System, Dallas, TX., Fullington H; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX., Halm EA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.; Harold C. Simmons Comprehensive Cancer Center, Dallas, TX.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2021 Nov; Vol. 17 (11), pp. e1738-e1752. Date of Electronic Publication: 2021 May 26.
DOI:	10.1200/OP.20.00889
Abstrakt:	Purpose: To determine whether emergency department (ED) visit history prior to cancer diagnosis is associated with ED visit volume after cancer diagnosis. Methods: This was a retrospective cohort study of adults (≥ 18 years) with an incident cancer diagnosis (excluding nonmelanoma skin cancers or leukemia) at an academic medical center between 2008 and 2018 and a safety-net hospital between 2012 and 2016. Our primary outcome was the number of ED visits in the first 6 months after cancer diagnosis, modeled using a multivariable negative binomial regression accounting for ED visit history in the 6-12 months preceding cancer diagnosis, electronic health record proxy social determinants of health, and clinical cancer-related characteristics. Results: Among 35,090 patients with cancer (49% female and 50% non-White), 57% had ≥ 1 ED visit in the 6 months immediately following cancer diagnosis and 20% had ≥ 1 ED visit in the 6-12 months prior to cancer diagnosis. The strongest predictor of postdiagnosis ED visits was frequent (≥ 4) prediagnosis ED visits (adjusted incidence rate ratio [aIRR]: 3.68; 95% CI, 3.36 to 4.02). Other covariates associated with greater postdiagnosis ED use included having 1-3 prediagnosis ED visits (aIRR: 1.32; 95% CI, 1.28 to 1.36), Hispanic (aIRR: 1.12; 95% CI, 1.07 to 1.17) and Black (aIRR: 1.21; 95% CI, 1.17 to 1.25) race, homelessness (aIRR: 1.95; 95% CI, 1.73 to 2.20), advanced-stage cancer (aIRR: 1.30; 95% CI, 1.26 to 1.35), and treatment regimens including chemotherapy (aIRR: 1.44; 95% CI, 1.40 to 1.48). Conclusion: The strongest independent predictor for ED use after a new cancer diagnosis was frequent ED visits before cancer diagnosis. Efforts to reduce potentially avoidable ED visits among patients with cancer should consider educational initiatives that target heavy prior ED users and offer them alternative ways to seek urgent medical care. Competing Interests: Arthur S. HongHonoraria: Medscape (I)Consulting or Advisory Role: Janssen (I), AbbVie (I)Speakers' Bureau: Janssen (I), AbbVie (I)Travel, Accommodations, Expenses: Janssen (I), AbbVie (I) D. Mark CourtneyStock and Other Ownership Interests: Attune MedicalConsulting or Advisory Role: Nabriva Therapeutics John V. CoxEmployment: University of Texas Southwestern Medical Center—Simmons Cancer CenterLeadership: Parkland Health SystemStock and Other Ownership Interests: Amgen, Medfusion, Merck, Pfizer, Johnson & JohnsonHonoraria: Association of Community Cancer Centers, American College of Physicians, National Comprehensive Cancer Network, National Academies of Science Engineering MedicineResearch Funding: US OncologyTravel, Accommodations, Expenses: American College of Physicians, Association of Community Cancer Centers, National Comprehensive Cancer NetworkOther Relationship: Mary Crowley Research Center, ASCO, Texas OncologyUncompensated Relationships: National Committee for Quality AssuranceNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz: